111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a note issued to investors on Saturday, September 13th,Weiss Ratings reports.
111 Price Performance
Shares of YI traded down $0.20 during midday trading on Friday, reaching $5.22. The stock had a trading volume of 30,826 shares, compared to its average volume of 21,741. 111 has a 1-year low of $4.14 and a 1-year high of $11.90. The company's fifty day simple moving average is $6.68 and its two-hundred day simple moving average is $7.58. The company has a market cap of $45.10 million, a price-to-earnings ratio of -6.21 and a beta of 0.46.
111 (NASDAQ:YI - Get Free Report) last announced its quarterly earnings data on Wednesday, September 17th. The company reported ($0.40) earnings per share for the quarter. The firm had revenue of $447.51 million for the quarter.
Institutional Investors Weigh In On 111
A hedge fund recently bought a new stake in 111 stock. Connor Clark & Lunn Investment Management Ltd. bought a new stake in 111, Inc. Sponsored ADR (NASDAQ:YI - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 11,338 shares of the company's stock, valued at approximately $92,000. Connor Clark & Lunn Investment Management Ltd. owned 0.13% of 111 at the end of the most recent reporting period. Institutional investors and hedge funds own 21.32% of the company's stock.
About 111
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Featured Articles
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
